Apeximmune Therapeutics and Erasmus Medical Center reported a new immune checkpoint that could expand the pool of patients benefiting from antitumor immunotherapy. The work positions the target as a potential lever to overcome current limitations in response rates, while setting up next-stage preclinical validation steps for the platform’s immuno-oncology approach.